Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Evaluation of the effect of chance correlations on variable selection using Partial Least Squares -Discriminant Analysis

  • Kuligowski, Julia
  • Pérez Guaita, David
  • Escobar, Javier
  • Guardia, Miguel de la
  • Vento, Máximo
  • Quintás, Guillermo
  • Ferrer, Alberto|||0000-0001-7244-5947
Variable subset selection is often mandatory in high throughput metabolomics and proteomics. However, depending on the variable to sample ratio there is a significant susceptibility of variable selection towards chance correlations. The evaluation of the predictive capabilities of PLSDA models estimated by cross-validation after feature selection provides overly optimistic results if the selection is performed on the entire set and no external validation set is available. In this work, a simulation of the statistical null hypothesis is proposed to test whether the discrimination capability of a PLSDA model after variable selection estimated by cross-validation is statistically higher than that attributed to the presence of chance correlations in the original data set. Statistical significance of PLSDA CV-figures of merit obtained after variable selection is expressed by means of p-values calculated by using a permutation test that included the variable selection step. The reliability of the approach is evaluated using two variable selection methods on experimental and simulated data sets with and without induced class differences. The proposed approach can be considered as a useful tool when no external validation set is available and provides a straightforward way to evaluate differences between variable selection methods., JE and JK acknowledge the "Sara Borrell" Grants (CD11/00154 and CD12/00667) from the Instituto Carlos III (Ministry of Economy and Competitiveness). DPG acknowledge the "V Segles" Grant provided by the University of Valencia to carry out this study. MV acknowledges the FISPI11/0313 Grant from the Instituto Carlos III (Ministry of Economy and Competitiveness). AF acknowledges the DPI2011-28112-C04-02 Grant from Spanish Ministry of Science and Innovation (MICINN). GQ acknowledges the financial support from the Spanish Ministry of Economy and Competitivity (SAF2012-39948).
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

A cellular and molecular basis for the selective desmopressin-induced ACTH release in Cushing disease patients: key role of AVPR1b receptor and potential therapeutic implications

  • Luque, Raúl M.
  • Ibáñez-Costa, Alejandro
  • López-Sánchez, Laura María
  • Jiménez Reina, L.
  • Venegas-Moreno, Eva
  • Gálvez-Moreno, M. Ángeles
  • Villa-Osaba, Alicia
  • Madrazo Atutxa, Ainara M.
  • Japón, Miguel Ángel
  • de la Riva, Andrés
  • Cano, David A.
  • Benito-López, Pedro
  • Soto-Moreno, Alfonso
  • Gahete Ortiz, Manuel D.
  • Leal-Cerro, Alfonso
  • Castaño, Justo P.
Context: Desmopressin is a synthetic agonist of vasopressin receptors (AVPRs). The desmopressin stimulation test is used in the diagnosis and postsurgery prognosis of Cushing disease (CD). However, the cellular and molecular mechanisms underlying the desmopressin-induced ACTH increase in patients with CD are poorly understood. Objective: The objectives of this study were to determine, for the first time, whether desmopressin acts directly and exclusively on pituitary corticotropinoma cells to stimulate ACTH expression/release and to elucidate the cellular and molecular mechanisms involved in desmopressin-induced ACTH increase in CD. Design: A total of 8 normal pituitaries (NPs), 23 corticotropinomas, 14 nonfunctioning pituitary adenomas, 17 somatotropinomas, and 3 prolactinomas were analyzed for AVPR expression by quantitative real-time RT-PCR. Primary cultures derived from corticotropinomas, nonfunctioning pituitary adenomas, somatotropinomas, prolactinomas, and NPs were treated with desmopressin, and ACTH secretion/expression, [Ca2+]i kinetics, and AVPR expression and/or proliferative response were evaluated. The relationship between AVPR expression and plasma adrenocorticotropin/cor-tisol levels obtained from desmopressin tests was assessed. Results: Desmopressin affects all functional parameters evaluated in corticotropinoma cells but not in NPs or other pituitary adenomas cells. These effects might be due to the dramatic elevation of AVPR1b expression levels found in corticotropinomas. In line with this notion, the use of an AVPR1b antagonist completely blocked desmopressin stimulatory effects. Remarkably, only AVPR1b expression was positively correlated with elevated plasma adrenocorticotropin levels in corticotropinomas. Conclusions: The present results provide a cellular and molecular basis to support the desmopressin stimulation test as a reliable, specific test for the diagnosis and postsurgery prognosis of CD. Furthermore, our data indicate that AVPR1b is responsible for the direct/exclusive desmopressin stimulatory pituitary effects observed in CD, thus opening the possibility of exploring AVPR1b antagonists as potential therapeutic tools for CD treatment.
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas

  • Luque, Raúl M.
  • Ibáñez-Costa, Alejandro
  • Vieira Neto, Leonardo
  • Taboada, Giselle F
  • Hormaechea-Agulla, Daniel
  • Kasuki, Leandro
  • Venegas-Moreno, Eva
  • Moreno-Carazo, Alberto
  • Gálvez-Moreno, M. Ángeles
  • Soto-Moreno, Alfonso
  • Kineman, Rhonda D
  • Culler, Michael D
  • Gahete Ortiz, Manuel D.
  • Gadelha, Monica R
  • Castaño, Justo P.
The GH/IGF1 response of somatotropinomas to somatostatin analogues (SSA) is associated with their pattern of somatostatin receptor (sst1-sst5) expression. Recently, we demonstrated that expression of a truncated sst5-variant (sst5TMD4) can influence the secretory response of somatotropinomas to SSA-therapy; however, its potential relationship with aggressive features (e.g. invasion/proliferation) is still unknown. Here, we show that sst5TMD4 is present in 50% of non-functioning pituitary-adenomas (NFPA) (n = 30) and 89% of somatotropinomas (n = 36), its expression levels being highest in somatotropinomas > > NFPAs > > > normal pituitaries (negligible expression; n = 8). In somatotropinomas, sst5TMD4 mRNA and protein levels correlated positively, and its expression was directly associated with tumor invasiveness (cavernous/sphenoid sinus), and inversely correlated with age and GH/IGF1 reduction after 3-6 months with octreotide-LAR therapy. GNAS+ somatotropinomas expressed lower sst5TMD4 levels. ROC analysis revealed sst5TMD4 expression as the only marker, within all sst-subtypes, capable to predict tumor invasiveness in somatotropinomas. sst5TMD4 overexpression increased cell viability in cultured somatotropinoma (n = 5). Hence, presence of sst5TMD4 associates with increased aggressive features and worse prognosis in somatotropinomas, thereby providing a potentially useful tool to refine somatotropinoma diagnosis, predict outcome of clinical response to SSA-therapy and develop new therapeutic targets.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Truncated Isoform of Somatostatin Receptor5 (sst5TMD4) Is Associated with Poorly Differentiated Thyroid Cancer

  • Puig Domingo, Manuel|||0000-0002-6744-7195
  • Luque, Raúl M.|||0000-0002-7585-1913
  • Reverter Calatayud, Jorge Luis|||0000-0003-0362-2035
  • López-Sánchez, Laura M.
  • Gahete, Manuel D.
  • Culler, Michael D.
  • Díaz-Soto, Gonzalo|||0000-0001-9743-9412
  • Lomeña, Francisco
  • Squarcia, Mattia
  • Mate Sanz, Jose Luís|||0000-0002-4829-3426
  • Mora, Mireia|||0000-0002-5887-5016
  • Fernández-Cruz, Laureano
  • Vidal, Oscar
  • Alastrue Vidal, Antonio|||0000-0002-8395-8438
  • Balibrea Del Castillo, José María|||0000-0002-0764-7179
  • Halperin, Irene|||0000-0003-3151-5990
  • Mauricio, Didac|||0000-0002-2868-0250
  • Castaño, Justo P.|||0000-0002-3145-7287
Somatostatin receptors (ssts) are expressed in thyroid cancer cells, but their biological significance is not well understood. The aim of this study was to assess ssts in well differentiated (WDTC) and poorly differentiated thyroid cancer (PDTC) by means of imaging and molecular tools and its relationship with the efficacy of somatostatin analog treatment. Thirty-nine cases of thyroid carcinoma were evaluated (20 PDTC and 19 WDTC). Depreotide scintigraphy and mRNA levels of sst-subtypes, including the truncated variant sst5TMD4, were carried out. Depreotide scans were positive in the recurrent tumor in the neck in 6 of 11 (54%) PDTC, and in those with lung metastases in 5/11 cases (45.4%); sst5TMD4 was present in 18/20 (90%) of PDTC, being the most densely expressed sst-subtype, with a 20-fold increase in relation to sst2. In WDTC, sst2 was the most represented, while sst5TMD4 was not found; sst2 was significantly increased in PDTC in comparison to WDTC. Five depreotide positive PDTC received octreotide for 3-6 months in a pilot study with no changes in the size of the lesions in 3 of them, and a significant increase in the pulmonary and cervical lesions in the other 2. All PDTC patients treated with octreotide showed high expression of sst5TMD4. ROC curve analysis demonstrated that only sst5TMD4 discriminates between PDTC and WDTC. We conclude that sst5TMD4 is overexpressed in PDTC and may be involved in the lack of response to somatostatin analogue treatment.